From sugar to fat: How the transcription factor XBP1 regulates hepatic lipogenesis.
Lipogenesis occurs primarily in the liver, where dietary carbohydrates control the expression of key enzymes in glycolytic and lipogenic pathways. We have recently discovered that the transcription factor XBP1, best known as a key regulator of the unfolded protein response (UPR), is required for de novo fatty acid synthesis in the liver, a function unrelated to its role in the UPR.(1) XBP1 protein expression is induced in the liver by a high carbohydrate diet and directly controls the induction of critical genes involved in fatty acid synthesis. Specific deletion of XBP1 in adult liver using an inducible approach results in profound hypocholesterolemia and hypotriglyceridemia, which could be attributed to diminished production of lipids in the liver. Notably, this phenotype is not associated with fatty liver (hepatic steatosis) or significant compromise in protein secretion. XBP1 joins an already rich field of transcriptional regulatory proteins in the control of hepatic lipogenesis. Its function in lipogenesis appears to be highly significant as evidenced by the phenotype of the genetic mutant strain. A more complete understanding of the mechanisms by which XBP1 accelerates de novo fatty acid synthesis in the liver while preserving normal hepatic lipid composition is highly relevant to the treatment of diseases such as atherosclerosis and metabolic syndrome that are associated with dyslipidemia. Since excess fat accumulation in the liver could result from increased hepatic fatty acid synthesis, compounds that inhibit XBP1 activation may also be useful therapeutics for the treatment of human alcoholic liver disease (ALD) and nonalcoholic fatty liver disease (NAFLD), increasingly common causes of morbidity and mortality in the United States.
Glimcher
Laurie H
LH
Department of Immunology and Infectious Diseases, Harvard School of Public Health, Boston, Massachusetts, USA. lglimche@hsph.harvard.edu
Lee
Ann-Hwee
AH
D000328:Adult; D002241:Carbohydrates / Q000502:physiology; D002784:Cholesterol / Q000172:deficiency; D004268:DNA-Binding Proteins / Q000187:drug effects / Q000235:genetics* / Q000378:metabolism; D004040:Dietary Carbohydrates / Q000494:pharmacology*; D050171:Dyslipidemias / Q000235:genetics; D005227:Fatty Acids / Q000096:biosynthesis; D005802:Genes, MHC Class II; D006801:Humans; D007333:Insulin Resistance / Q000235:genetics; D008055:Lipids / Q000096:biosynthesis*; D008099:Liver / Q000502:physiology*; D008659:Metabolic Diseases / Q000235:genetics*; D024821:Metabolic Syndrome / Q000453:epidemiology; D009765:Obesity / Q000453:epidemiology; D012333:RNA, Messenger / Q000235:genetics; D000071701:Regulatory Factor X Transcription Factors; D014157:Transcription Factors / Q000187:drug effects / Q000235:genetics* / Q000378:metabolism; D014280:Triglycerides / Q000172:deficiency; D000071717:X-Box Binding Protein 1
D002241:Carbohydrates; D004268:DNA-Binding Proteins; D004040:Dietary Carbohydrates; D005227:Fatty Acids; D008055:Lipids; D012333:RNA, Messenger; D000071701:Regulatory Factor X Transcription Factors; D014157:Transcription Factors; D014280:Triglycerides; D000071717:X-Box Binding Protein 1; C000605543:XBP1 protein, human; D002784:Cholesterol